Hudson Bay Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Hudson Bay Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,261,609	Closed	-$12.7M	–	1199
2022 Q4	$12.7M	Hold	1,261,609	–	–	0.13%	133
2022 Q3	$12.5M	Hold	1,261,609	–	–	0.11%	126
2022 Q2	$12.5M	Buy	1,261,609 +751,824	+147%	+$7.37M	0.09%	144
2022 Q1	$5.02M	Buy	509,785 +18,159	+4%	+$179K	0.07%	359
2021 Q4	$4.84M	Buy	491,626 +101,696	+26%	+$998K	0.05%	355
2021 Q3	$3.8M	Hold	389,930	–	–	0.05%	449
2021 Q2	$3.77M	Buy	389,930 +189,930	+95%	+$1.85M	0.05%	436
2021 Q1	$1.94M	Buy	+200,000	New	+$1.94M	0.02%	571

Hudson Bay Capital Management's BIOT Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 1,261,609 shares — an estimated $12.7M sold.

Hudson Bay Capital Management first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $12.7M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Hudson Bay Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 1,261,609 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $12.7M.
Hudson Bay Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Hudson Bay Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $12.7M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.